KALARIS THERAPEUTICS, INC. Proceeds from Issuance of Redeemable Convertible Preferred Stock
KALARIS THERAPEUTICS, INC. (KLRS) reported Proceeds from Issuance of Redeemable Convertible Preferred Stock of $1.59 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock · last filed 2026-03-17
- KALARIS THERAPEUTICS, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2024-12-31 was $0.00.
- KALARIS THERAPEUTICS, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2024-09-30 was $0.00.
- KALARIS THERAPEUTICS, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2024-06-30 was $0.00.
- KALARIS THERAPEUTICS, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2024-03-31 was $1.59M.
- KALARIS THERAPEUTICS, INC. proceeds from issuance of redeemable convertible preferred stock for fiscal 2024 was $1.59M.
| Period end | Proceeds from Issuance of Redeemable Convertible Preferred Stock 3 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 6 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 9 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $1.59M 10-K · filed 2026-03-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $1.59M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.59M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $1.59M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |